Tags

Type your tag names separated by a space and hit enter

Mogamulizumab for the treatment of T-cell lymphoma.

Abstract

INTRODUCTION

T-cell lymphoma is a relatively rare hematologic malignancy that accounts for 10-20% of non-Hodgkin lymphomas. Treatment strategies for T-cell lymphomas are different from that for B-cell lymphomas and have poor prognoses. Among various subtypes of T-cell lymphomas, adult T-cell leukemia-lymphoma (ATL) has the worst prognosis. To achieve further improvement in the treatment outcome of T-cell lymphomas, several novel agents such as brentuximab vedotin, lenalidomide, romidepsin, and pralatrexate are actively being studied. Mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, is one of the promising agents for CCR4-positive T-cell lymphomas, especially for ATL. Areas covered: First, basic information about the current treatment strategy of T-cell lymphomas including ATL is described. Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas. Expert opinion: Mogamulizumab has potent clinical efficacy against CCR4-positive T-cell lymphomas, especially against ATL. Among various toxicities associated with mogamulizumab, skin eruptions are the most significant. Although there are several effective competitors, mogamulizumab has a unique mechanism and is expected to be a key agent for treating CCR4-positive T-cell lymphomas, especially ATL.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.

    a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.

    Source

    Expert opinion on biological therapy 17:9 2017 09 pg 1145-1153

    MeSH

    Antibodies, Monoclonal, Humanized
    Antineoplastic Agents
    Clinical Trials as Topic
    Half-Life
    Humans
    Immunohistochemistry
    Leukemia-Lymphoma, Adult T-Cell
    Lymphoma, T-Cell
    Neoplasm Recurrence, Local
    Receptors, CCR4
    Skin Diseases
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    28649848

    Citation

    Makita, Shinichi, and Kensei Tobinai. "Mogamulizumab for the Treatment of T-cell Lymphoma." Expert Opinion On Biological Therapy, vol. 17, no. 9, 2017, pp. 1145-1153.
    Makita S, Tobinai K. Mogamulizumab for the treatment of T-cell lymphoma. Expert Opin Biol Ther. 2017;17(9):1145-1153.
    Makita, S., & Tobinai, K. (2017). Mogamulizumab for the treatment of T-cell lymphoma. Expert Opinion On Biological Therapy, 17(9), pp. 1145-1153. doi:10.1080/14712598.2017.1347634.
    Makita S, Tobinai K. Mogamulizumab for the Treatment of T-cell Lymphoma. Expert Opin Biol Ther. 2017;17(9):1145-1153. PubMed PMID: 28649848.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Mogamulizumab for the treatment of T-cell lymphoma. AU - Makita,Shinichi, AU - Tobinai,Kensei, Y1 - 2017/07/03/ PY - 2017/6/27/pubmed PY - 2017/12/7/medline PY - 2017/6/27/entrez KW - ATL KW - Adult T-cell leukemia-lymphoma KW - CCR4 KW - CTCL KW - Mogamulizumab KW - PTCL KW - T-cell lymphoma SP - 1145 EP - 1153 JF - Expert opinion on biological therapy JO - Expert Opin Biol Ther VL - 17 IS - 9 N2 - INTRODUCTION: T-cell lymphoma is a relatively rare hematologic malignancy that accounts for 10-20% of non-Hodgkin lymphomas. Treatment strategies for T-cell lymphomas are different from that for B-cell lymphomas and have poor prognoses. Among various subtypes of T-cell lymphomas, adult T-cell leukemia-lymphoma (ATL) has the worst prognosis. To achieve further improvement in the treatment outcome of T-cell lymphomas, several novel agents such as brentuximab vedotin, lenalidomide, romidepsin, and pralatrexate are actively being studied. Mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, is one of the promising agents for CCR4-positive T-cell lymphomas, especially for ATL. Areas covered: First, basic information about the current treatment strategy of T-cell lymphomas including ATL is described. Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas. Expert opinion: Mogamulizumab has potent clinical efficacy against CCR4-positive T-cell lymphomas, especially against ATL. Among various toxicities associated with mogamulizumab, skin eruptions are the most significant. Although there are several effective competitors, mogamulizumab has a unique mechanism and is expected to be a key agent for treating CCR4-positive T-cell lymphomas, especially ATL. SN - 1744-7682 UR - https://www.unboundmedicine.com/medline/citation/28649848/Mogamulizumab_for_the_treatment_of_T_cell_lymphoma_ L2 - http://www.tandfonline.com/doi/full/10.1080/14712598.2017.1347634 DB - PRIME DP - Unbound Medicine ER -